AzurRx (AZRX) Corporate Media Kit

10 EPI Therapeutic Indication Phase 2 Clinical Trials Development Phase Discovery Pre-Clinical Phase 1 Phase 2 Phase 3 CP patients (doses up to 2.2g) Dose Escalation Study CF patients (2.2g) Bridging Dose Safety Study CF patients (2.2g & 4.4g in enteric capsules) Dose Escalation Study Severe CF patients (doses up to 2.2g) Dose Escalation Study Topline Results Expected Q1 2021 Current Status GI Therapeutic Product Pipeline MS1819 – Yeast recombinant lipase Ongoing Ongoing Completed Completed Completed l t